Prasad Vankineni, MD
Gastroenterology · Huntsville, ALNPI 1700958873
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 604 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 28.8% of the total.
Across 604 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- Gilead$666
- Pfizer$551
- Takeda Pharmaceuticals U.S.A., Inc.$472
- plus $3K from 30 others
What the payments were for
- Consulting fees$140%
- Food & beverage$10,13798%
- Education$1662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 183 | $2,969 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 106 | $1,399 |
| Johnson & Johnson | 63 | $1,120 |
| Gilead | 24 | $666 |
| Pfizer | 36 | $551 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $472 |
| QOL Medical, LLC | 19 | $446 |
| Madrigal Pharmaceuticals | 8 | $217 |
| Ironwood Pharmaceuticals, Inc | 13 | $209 |
| Sanofi | 10 | $204 |
| Ardelyx, Inc. | 9 | $185 |
| Regeneron Healthcare Solutions, Inc. | 7 | $162 |
| Ferring Pharmaceuticals Inc. | 9 | $150 |
| UCB, Inc. | 10 | $144 |
| Aimmune Therapeutics, Inc. | 7 | $140 |
| Phathom Pharmaceuticals, Inc. | 14 | $133 |
| Evoke Pharma, Inc. | 7 | $131 |
| Nestle Healthcare Nutrition Inc. | 7 | $119 |
| Intercept Pharmaceuticals, Inc. | 7 | $117 |
| Boston Scientific | 2 | $115 |
| Merck | 5 | $94 |
| Lilly USA, LLC | 4 | $83 |
| Bristol Myers Squibb | 5 | $75 |
| Redhill Biopharma Inc. | 4 | $70 |
| Celltrion USA Inc. | 4 | $66 |
| Intra-sana Laboratories | 3 | $61 |
| Braintree Laboratories, Inc. | 3 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Orphalan Inc | 1 | $25 |
| Concordia Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Mylan Institutional Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$123
How this compares
$10,316 in reported general payments places this provider in the 80th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 20 | $563,684 |
| Humira(Cf) PenAdalimumab | 35 | $228,150 |
| LinzessLinaclotide | 95 | $80,304 |
| ViberziEluxadoline | 24 | $32,164 |
| TrulancePlecanatide | 29 | $26,160 |
| MovantikNaloxegol Oxalate | 47 | $22,006 |
| Dexlansoprazole DrDexlansoprazole | 44 | $15,720 |
| Mesalamine | 28 | $15,161 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 205 | $12,351 |
| Colesevelam Hcl | 45 | $10,985 |
| Sucralfate | 243 | $9,422 |
| Famotidine | 495 | $7,346 |
| Budesonide DrBudesonide | 29 | $4,945 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 24 | $4,109 |
| Omeprazole | 275 | $3,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,120 | $563,68420 claims |
| AbbVieLinzess, Viberzi | $2,969 | $112,468119 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $1,399 | $27,78841 claims |
| Redhill Biopharma Inc.Movantik | $70 | $22,00647 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $150 | $4,10924 claims |
| Braintree Laboratories, Inc.Sutab | $47 | $1,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Huntsville
- John-Paul VoelkelHuntsville$17K
- Meredith RoathHuntsville$16K
- Charles BillingsHuntsville$16K
- Dino FerranteHuntsville$15K
- Suresh KarneHuntsville$12K
- Rami HawariHuntsville$10K
- Eghierhua UgheokeHuntsville$10K
- Jason KinzelHuntsville$10K
- Keta VaidyaHuntsville$9K
- Michael DohrenwendHuntsville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.